With the growing number of gene variants, signatures and pan-tumor biomarkers that are targetable with FDA-approved therapies (e.g., TMB, MSI, ALK, BRAF, ROS1, NTRK), targeted CGP is progressively considered as standard of care by many ordering oncologists and pathologists in the management of patients with advanced cancers. This evidence concerns the gene ROS1 and neoplasm.